Zobrazeno 1 - 1
of 1
pro vyhledávání: '"BUZDAR, A"'
Autor:
Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Boccardo, F, Coates, A, Coombes, RC, Cuzick, J, Dubsky, P, Gnant, M, Kaufmann, M, Kilburn, L, Perrone, F, Rea, D, Thuerlimann, B, Van de Velde, C, Pan, H, Peto, R, Davies, C, Gray, R, Baum, M, Buzdar, A, Sestak, I, Markopoulos, C, Fesl, C, Jakesz, R, Colleoni, M, Gelber, R, Regan, M, Von Minckwitz, G, Snowdon, C, Goss, P, Pritchard, K, Anderson, S, Costantino, J, Mamounas, E, Ohashi, Y, Watanabe, T, Bastiaannet, E
Publikováno v:
Lancet, 386(10001), 1341-1352. Elsevier Science
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC
Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.Methods We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor-posit